



iJRASET

International Journal For Research in
Applied Science and Engineering Technology



INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Volume: 12 **Issue:** XII **Month of publication:** December 2024

DOI: <https://doi.org/10.22214/ijraset.2024.66098>

www.ijraset.com

Call: ☎ 08813907089

E-mail ID: ijraset@gmail.com

A Pharmacovigilance Study on Anti-Asthmatic Agent

Sandip Mande¹, Sakshi Maknikar², Varsha Kshirsagar³, Prajyot Manjramkar⁴, Arati Landage⁵

Shivlingeshwar College of Pharmacy, Almala

Abstract: Pharmacovigilance plays a critical role in ensuring the safety and efficacy of anti-asthmatic agents, including inhaled corticosteroids (ICS), long-acting beta-agonists (LABAs), and leukotriene receptor antagonists (LTRAs). This study evaluates adverse drug reactions (ADRs) associated with these medications, emphasizing their clinical impact, risk factors, and patient outcomes. A systematic approach, including spontaneous ADR reporting, database reviews, and post-marketing surveillance, was utilized to identify patterns of drug-related complications, such as dysphonia, oral candidiasis, and cardiovascular risks. Findings highlight the importance of monitoring combination therapies, optimizing medication use, and enhancing patient education to improve asthma management while minimizing risks. Future directions include integrating pharmacogenomic data into safety assessments to personalize asthma treatment.


Keywords: Pharmacovigilance, Anti-asthmatic agents, Adverse drug reactions (ADRs), Inhaled corticosteroids (ICS), Long-acting beta-agonists (LABA), Leukotriene receptor antagonists (LTRAs), Asthma management

I. INTRODUCTION

Pharmacovigilance is the science and activities related to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problems, is crucial in ensuring the safe use of medications. This is especially significant in the context of asthma, a chronic respiratory condition that affects millions of individuals worldwide. Anti-asthmatic drugs, including bronchodilators, corticosteroids, leukotriene modifiers and monoclonal antibodies, are commonly prescribed to manage asthma symptoms and improve lung function. However, despite their therapeutic benefits, these medications can lead to adverse drug reactions (ADRs), which require close monitoring to minimize risks and ensure patient safety (1). Asthma treatments, particularly inhaled corticosteroids (ICS) and long-acting beta-agonists (LABAs), have been associated with a range of adverse events. ICS, while effective in reducing inflammation and preventing asthma attacks, may contribute to side effects such as oral candidiasis, dysphonia, and, rarely, systemic effects like osteoporosis and adrenal suppression (2). LABAs, when used without an inhaled corticosteroid, have been linked to increased risk of severe asthma exacerbations and asthma-related deaths (3). Additionally, newer biologic agents such as monoclonal antibodies, although revolutionary in severe asthma treatment, can induce immune-related side effects, including anaphylaxis and injection site reactions (1). Pharmacovigilance in asthma aims not only to detect and report these ADRs but also to understand the underlying mechanisms, assess the long-term safety of asthma medications, and guide clinical practice. Real-world data collection, through spontaneous reporting systems and patient registries, is essential for identifying rare and long-term side effects that may not be evident in clinical trials. Effective pharmacovigilance systems help balance the benefits and risks of anti-asthmatic drugs, ensuring safer and more effective management of asthma (3).

A. Asthma

Asthma is a chronic inflammatory disorder of the airways, characterized by episodes of wheezing, shortness of breath, chest tightness, and coughing, particularly at night or in the early morning. These symptoms occur due to airway hyperresponsiveness to a variety of triggers, such as allergens, respiratory infections, air pollutants, cold air, and exercise. Asthma can range from mild intermittent symptoms to severe, persistent conditions that significantly impact a person's quality of life.



B. Pathophysiology of Asthma

Asthma is a chronic inflammatory disease of the airways that involves complex interactions between inflammatory cells, mediators, and airway structural cells. The underlying pathophysiology of asthma involves both bronchoconstriction and inflammation, leading to airway hyperresponsiveness, obstruction, and remodeling over time. The pharmacological understanding of asthma focuses on the key pathways involved in these processes, which can be targeted by various medications such as bronchodilators, corticosteroids, and leukotriene inhibitors.

1) Airway Inflammation

- **Inflammatory Cells:** In asthma, the activation of T-helper (Th2) cells leads to the recruitment of eosinophils, mast cells, and neutrophils into the airways. Th2 cells release cytokines (such as IL-4, IL-5, and IL-13) that promote inflammation and mucus production. This process increases airway resistance and causes obstruction.
- **Mediators:** Key mediators of asthma include histamine, prostaglandins, and leukotrienes, which are released from mast cells, eosinophils, and other cells during allergic reactions. These substances lead to airway edema, smooth muscle contraction, and mucus secretion, which further narrow the airways (1, 2).

2) Bronchoconstriction

- Bronchospasm occurs when smooth muscle surrounding the bronchi constricts, limiting airflow. This is mainly mediated by acetylcholine through muscarinic receptors in the smooth muscle (3). Beta-adrenergic receptor agonists, like albuterol, help relax the smooth muscles and reverse bronchoconstriction.
- Muscarinic antagonists (e.g., ipratropium) block acetylcholine, which reduces bronchospasm and improves airflow (4).

3) Airway Hyper Responsiveness

- Patients with asthma exhibit increased airway responsiveness to a variety of stimuli such as allergens, viral infections, cold air, or exercise. This heightened sensitivity results from airway inflammation and changes in airway smooth muscle function. Leukotrienes and cytokines contribute to this hyperreactivity by promoting inflammation and bronchoconstriction (5).

4) Airway Remodeling

- Over time, chronic inflammation leads to structural changes in the airway wall, including fibrosis, smooth muscle hypertrophy, and goblet cell hyperplasia (increased mucus production). This remodeling is partially driven by IL-13 and TGF- β (transforming growth factor-beta), which contribute to fibrosis and structural changes. These changes cause permanent airflow limitation in some patients (6).

C. Antigen-Antibody Mechanism in Asthma

Asthma pathophysiology involves a complex interaction between allergens (antigens) and antibodies on mast cells, which leads to the release of inflammatory mediators that cause asthma symptoms. Here are the simple steps:

1) Exposure to Allergens (Antigen)

- When an individual with asthma is exposed to an allergen (like pollen, dust, or pet dander), their immune system recognizes it as harmful.

2) Binding of Allergen to IgE Antibodies

- In asthma, IgE antibodies (immunoglobulin E) are produced in response to the allergen. These antibodies bind to mast cells in the respiratory tract (particularly in the airways).

3) Activation of Mast Cells

- The binding of the allergen to IgE antibodies on mast cells triggers the activation of these cells. Once activated, mast cells undergo degranulation.

4) Release of Inflammatory Mediators

- Histamine causes bronchoconstriction (tightening of the airway muscles), resulting in narrowing of the airways.
- Leukotrienes and prostaglandins further contribute to inflammation and airway obstruction.

5) *Bronchoconstriction and Inflammation:*

- The release of these mediators leads to swelling and increased mucus production in the airways, which causes difficulty breathing and worsens airway obstruction.

6) *Development of Symptoms:*

- The result is the classic symptoms of asthma: wheezing, shortness of breath, coughing, and chest tightness.

II. EPIDEMIOLOGY OF ASTHMA

The global epidemiology of asthma reflects significant variations in prevalence and burden across different regions, age groups, and socioeconomic contexts. Asthma is one of the most common chronic respiratory diseases worldwide, affecting both children and adults.

According to the Global Burden of Disease (GBD) Study, 262 million people were living with asthma in 2019, with an age-standardized rate of approximately 3416 cases per 100,000 individuals are generally higher in high-income countries, with regions like North America, Europe, and Oceania reporting some of the highest rates of asthma symptoms, especially among children and adolescents. Around 30-50% asthma experience severe symptoms, which significantly impact daily life. The burden of asthma, measured in terms of disability-adjusted life years (DALYs), remains substantial, particularly in middle-income countries. Asthma's prevalence appears to have increased in recent years, especially in urban areas, which are associated with higher environmental and pollution risks.

These trends highlight the importance of understanding the complex interplay between genetic, environmental, and socioeconomic factors that shape asthma's global impact.

A. *Etiology of Asthma*

The etiology of asthma is multifactorial, involving a complex interplay of genetic and environmental factors. The development of asthma can be attributed to both inherited genetic predispositions and exposure to environmental factors during critical periods of development, such as early childhood or in utero.

Below are the primary contributors to asthma's etiology:

1) *Genetic Factors*

- Asthma has a strong genetic component, with a family history of asthma, allergic diseases (like eczema or hay fever), or other respiratory conditions significantly increasing the risk of developing asthma. Multiple genes involved in immune system regulation and inflammatory pathways are linked to asthma. Notably, genes encoding for interleukins (e.g., IL-4, IL-5) and receptors involved in airway inflammation and responsiveness (e.g., β -adrenergic receptors) have been associated with asthma risk (1, 2).
- Genome-wide association studies (GWAS) have identified several specific genetic variants that predispose individuals to asthma, particularly those influencing the immune response, airway remodeling, and allergic inflammation (3).

2) *Environmental Factors*

- Allergens: Exposure to environmental allergens like dust mites, pollen, pet dander, and mold is one of the most significant triggers for asthma, particularly in genetically susceptible individuals. These allergens provoke an immune response in the airways, leading to inflammation and hyperresponsiveness (4).
- Air Pollution: Exposure to air pollutants, including particulate matter (PM), ozone, and nitrogen dioxide (NO₂), is another critical environmental risk factor for asthma. Long-term exposure to these pollutants, particularly in urban areas, has been associated with increased asthma incidence and exacerbation of symptoms (5, 6).
- Respiratory Infections: Viral infections, especially in early childhood, such as those caused by rhinoviruses and respiratory syncytial virus (RSV), are known to increase the likelihood of asthma development later in life. These infections can alter the immune system's response, making the airways more susceptible to allergic triggers (7).
- Diet and Obesity: Poor dietary habits and obesity are becoming increasingly recognized as contributing factors in the development of asthma. Studies have found associations between low intake of antioxidants, vitamins, and an increased risk of asthma. Obesity, especially in adults, has been linked to both the onset of asthma and the worsening of symptoms (8).

III. CLINICAL MANIFESTATIONS OF ASTHMA

The clinical presentation of asthma is variable and can range from mild, intermittent symptoms to severe, persistent manifestations. Common clinical features include:

- 1) Wheezing: A high-pitched whistling sound heard during exhalation, often a hallmark of asthma, caused by airflow obstruction and airway narrowing (1, 2).
- 2) Coughing: Particularly at night or early in the morning, coughing can be a significant symptom of asthma. It is often dry and non-productive but may be associated with increased mucus production during exacerbations (3).
- 3) Shortness of Breath: Patients often experience difficulty breathing, especially during physical activity or at night, due to narrowing of the airways (4).
- 4) Chest Tightness: A feeling of pressure or constriction in the chest is common, which can feel like a "heavy" or "tight" chest (5, 6).
- 5) Exacerbations: Sudden worsening of symptoms, often triggered by allergens, exercise, or respiratory infections. These episodes can lead to increased frequency of wheezing, coughing, and difficulty in breathing (7).
- 6) Variability of Symptoms: Asthma symptoms tend to vary over time and may worsen in specific circumstances, such as during exposure to environmental triggers (dust, smoke, cold air), or viral infections (8, 9).

A. *Diagnosis of Asthma*

The diagnosis of asthma typically involves a combination of clinical evaluation, lung function tests, and detailed patient history. Healthcare providers use these methods to identify asthma symptoms, rule out other conditions, and confirm the presence of airway obstruction and hyperresponsiveness. Here are the primary steps in diagnosing asthma:

1) *Patient History*

- A thorough medical history is essential. Key elements include chronic cough, wheezing, shortness of breath, and chest tightness (often worsening at night or after exercise).
- The history also looks for triggers such as allergens, cold air, viral infections, or exposure to irritants (e.g., smoke or pollutants) (1, 2).

2) *Physical Examination*

- During an asthma examination, signs such as wheezing on auscultation and prolonged expiration may be observed. However, normal examination findings do not exclude asthma, particularly if the patient is not currently experiencing symptoms (3).

3) *Spirometry*

- Spirometry is the most common test used to diagnose asthma and assess lung function. It measures the forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC). A reduced FEV1/FVC ratio indicates airflow limitation (4).
- Bronchodilator reversibility testing: A positive response (increase in FEV1 by more than 12%) to a bronchodilator (e.g., salbutamol) supports the diagnosis of asthma by showing reversible airway obstruction (5).

4) *Peak Expiratory Flow (PEF) Measurement*

- PEF monitoring can help in diagnosing asthma, especially if spirometry is not available or to assess asthma control over time. Variability in PEF readings (more than 20%) between morning and evening suggests asthma (6).

5) *Methacholine Challenge*

- This test involves inhaling methacholine, a substance that causes bronchoconstriction. A positive test (significant decrease in FEV1) indicates airway hyperresponsiveness, supporting asthma diagnosis, particularly in cases with unclear spirometry results (7).

6) *Allergy Testing*

- Skin prick tests or serum IgE testing may be used to identify allergens that trigger asthma symptoms, helping in the identification of allergic asthma. Elevated levels of IgE can indicate an allergic response (8).

7) *Exclusion of Other Conditions*

- The healthcare provider may also rule out other conditions such as chronic obstructive pulmonary disease (COPD), gastroesophageal reflux disease (GERD), or vocal cord dysfunction that could mimic asthma symptoms (9).

IV. TREATMENT OF ASTHMA

1) *Bronchodilators (Relievers)*

- Short-acting beta-agonists (SABA): These are fast-acting medications like salbutamol (albuterol) that quickly relieve bronchoconstriction and are used for immediate symptom relief during asthma attacks (1).
- Long-acting beta-agonists (LABA): Medications like salmeterol or formoterol help in long-term control by maintaining bronchodilation, often used in combination with inhaled corticosteroids (ICS) (2).

2) *Anti-inflammatory Drugs*

- Inhaled Corticosteroids (ICS): These are the cornerstone of long-term asthma management. Drugs like fluticasone or budesonide reduce airway inflammation, control symptoms, and prevent exacerbations (3).
- Oral Corticosteroids: For acute exacerbations, short courses of prednisone may be used to reduce severe inflammation (4).
- Leukotriene Modifiers: Medications like montelukast and zafirlukast inhibit the action of leukotrienes, which are inflammatory mediators that cause bronchoconstriction and inflammation (5).

3) *Mast Cell Stabilizers*

- Cromolyn sodium and nedocromil are used to prevent mast cell degranulation and the release of histamine, although they are less commonly used today (7).

4) *Anticholinergics*

- Ipratropium bromide is a short-acting muscarinic antagonist used in combination with other medications to provide relief during asthma exacerbations.

A. *Bronchodilator*

Mechanism of Action (MOA) of Bronchodilators

1) *Activation of Beta-Receptors*

- Bronchodilators act primarily by targeting beta-adrenergic receptors (especially beta-2 receptors) located on the smooth muscles of the airways.
- Beta-2 agonists (like albuterol) bind to these receptors.

2) *Increased cAMP Levels*

- Once activated, beta-2 receptors stimulate adenylate cyclase, an enzyme that converts ATP to cyclic adenosine monophosphate (cAMP).

3) *Smooth Muscle Relaxation*

- The increase in cAMP leads to activation of protein kinase A (PKA), which then reduces the intracellular calcium levels. Lower calcium levels in the smooth muscle cells cause relaxation of the muscles around the bronchi.

4) *Bronchodilation*

- This relaxation results in the widening of the airways (bronchodilation), allowing for easier airflow and reducing symptoms like wheezing, shortness of breath, and cough.

5) *Inhibition of Inflammatory Mediators:*

- In addition to bronchodilation, beta-2 agonists may also have a mild anti-inflammatory effect by inhibiting the release of pro-inflammatory mediators from mast cells and other immune cells in the airway (7).

Table: Bronchodilators – Drugs, Doses, and Routes of Administration

Class	Drug	Dosage	Route of Administration
Short-Acting Beta-Agonists (SABA)	Albuterol	90 mcg per puff (2 puffs every 4-6 hours as needed)	Inhalation (MDI, Nebulizer)
	Levalbuterol	45 mcg per puff (2 puffs every 4-6 hours as needed)	Inhalation (MDI, Nebulizer)
Long-Acting Beta-Agonists (LABA)	Salmeterol	50 mcg per puff (1 puff twice daily)	Inhalation (MDI)
	Formoterol	12 mcg per puff (1 puff twice daily)	Inhalation (MDI, Nebulizer)
Anticholinergics (SAMA, LAMA)	Ipratropium bromide	18 mcg per puff (2 puffs 3-4 times daily)	Inhalation (MDI, Nebulizer)
	Tiotropium	18 mcg per day	Inhalation (HandiHaler)
Methylxanthines	Theophylline	100-200 mg every 12 hours	Oral (Tablet, Liquid)

B. Inhaled Corticosteroids

Mechanism of Action (MOA) of Inhaled Corticosteroids (ICS) in Asthma:

1) Binding to Glucocorticoid Receptors

- ICS drugs enter airway cells and bind to glucocorticoid receptors (GR) present in the cytoplasm. This complex then translocates to the nucleus of the cell.

2) Modulation of Gene Expression

- The steroid-receptor complex acts as a transcription factor, either activating or suppressing the expression of specific genes. This leads to the reduction of pro-inflammatory proteins like cytokines, chemokines, and adhesion molecules while increasing anti-inflammatory proteins like lipocortin-1.

3) Inhibition of Inflammatory Mediators

- ICS inhibit the release of inflammatory mediators such as histamine, leukotrienes, and interleukins (e.g., IL-4, IL-5, IL-13), which contribute to airway inflammation and bronchoconstriction.

4) Reduction of Immune Cell Recruitment

- ICS prevent the activation and recruitment of inflammatory cells like eosinophils, neutrophils, and mast cells. This helps in reducing the ongoing inflammatory response and bronchoconstriction.

5) Decrease in Airway Hyperresponsiveness

- By reducing inflammation, ICS help to reduce the airway's exaggerated response to various triggers (such as allergens, cold air, and pollutants), preventing bronchoconstriction and improving airflow.

Drug	Route of Administration (ROA)	Dosage Regimen
Fluticasone	Inhalation (MDI, DPI)	44–110 mcg per puff (1-2 puffs twice daily)
Budesonide	Inhalation (MDI, DPI)	200 mcg per puff (1-2 puffs twice daily)
Beclometasone	Inhalation (MDI, DPI)	50–200 mcg per puff (1-2 puffs twice daily)

C. Leukotriene Antagonist

Mechanism of Action (MOA) of Leukotriene Receptor Antagonists (LTRAs)

Leukotriene Receptor Antagonists (LTRAs) are used in the treatment of asthma and allergic rhinitis. Their general mechanism of action includes the following steps:

1) Inhibition of Leukotriene Receptors:

- LTRAs, such as Montelukast and Zafirlukast, work by binding to cysteinyl leukotriene receptors (CysLT1) on the surface of bronchial smooth muscle cells, endothelial cells, and immune cells.
- Leukotrienes (such as LTC₄, LTD₄, and LTE₄) are inflammatory mediators released by mast cells, eosinophils, and basophils during allergic reactions and asthma exacerbations. These leukotrienes normally bind to CysLT1 receptors to cause bronchoconstriction, mucus secretion, and inflammation.

Drug	Route of Administration (ROA)	Dosage Regimen
Montelukast	Oral (Tablet, Chewable)	10 mg daily in the evening
Zafirlukast	Oral (Tablet)	20 mg twice daily (before meals)

D. Mast Cell Stabilizer

Mechanism of Action (MOA) of Mast Cell Stabilizers

Mast cell stabilizers, such as Cromolyn Sodium and Nedocromil, are used in asthma management to prevent allergic reactions and reduce airway inflammation. Their mechanism of action involves the following steps:

1) Inhibition of Mast Cell Degranulation

- Mast cells are immune cells that release a variety of pro-inflammatory mediators, such as histamine, leukotrienes, and cytokines, when triggered by allergens or irritants. Mast cell stabilizers prevent the activation and degranulation of these mast cells by stabilizing their membranes. This reduces the release of inflammatory mediators, which are responsible for causing bronchoconstriction and inflammation.

2) Blocking Early-Phase Allergic Reactions

- Mast cell stabilizers inhibit the early-phase allergic response triggered by the binding of allergens to IgE antibodies on mast cells. By stabilizing the mast cell membranes, the drugs prevent the release of histamine and other chemicals, thus preventing the cascade of allergic reactions that can lead to asthma symptoms such as wheezing and breathlessness.

Drug	Route of Administration (ROA)	Dosage Regimen
Cromolyn Sodium	Inhalation (Nebulizer, MDI)	800 mcg (1 vial) 4 times daily (or 2 puffs via MDI, 4 times daily)

V. LITERATURE SURVEY

- Findings: A comprehensive pharmacovigilance study involving 150 bronchial asthma patients revealed 33 ADRs, with oral thrush (33.33%) being the most common. ADRs were primarily associated with inhalational corticosteroids like Beclomethasone (58.33%) and Budesonide (25%). Severity assessments classified 75.76% of ADRs as mild, and causality evaluation categorized 48.49% as probable.

Title: Pharmacovigilance Study of Antiasthmatic Agents in Patients of Bronchial Asthma at a Tertiary Care Centre

Authors: U.P. Gawali & A. Deshkar

- Findings: Beta-2 agonists, such as Salbutamol, were found to cause systemic ADRs like palpitations, tremors, and headaches, especially at higher doses or prolonged usage. These ADRs underscore the importance of monitoring patients receiving high-dose therapies.

Title: Acute Electrophysiologic Effects of Inhaled Salbutamol in Humans

Authors: Kallergis EM et al.

- 3) Findings: Improper use of inhalers frequently caused throat irritation, cough, and dry mouth. This study recommended clinical pharmacist interventions to train patients on proper inhaler techniques to reduce ADR incidence and improve therapeutic efficacy.

Title: Assessment of Therapeutic Performances of Inhalation Aerosols and Clinical Pharmacist's Services in PFT Lab

Authors: Bajaj A et al.

- 4) Findings: A collaborative study on ADR monitoring emphasized the critical role of pharmacovigilance systems in minimizing the occurrence and severity of ADRs across diverse medications, highlighting a universal need for better ADR reporting mechanisms.

Title: Monitoring the Adverse Profile of Atenolol: A Collaborative Study

Authors: Garg KC et al.

- 5) Findings: Inhalational corticosteroids like Beclomethasone and Budesonide were strongly associated with oral thrush and candidiasis. Recommendations included oral hygiene practices such as rinsing and brushing teeth post-inhalation to minimize these risks.

Title: Impact of Inhalational Therapy on Oral Health

Authors: Godara N et al.

- 6) Findings: Antifungal interventions and enhanced oral hygiene regimens were identified as effective strategies for managing oral thrush in patients receiving long-term corticosteroid therapy.

Title: Interventions for Treating Oral Candidiasis for Patients with Cancer Receiving Treatment

Authors: Worthington HV et al.

- 7) Findings: Candida infections were commonly linked to prolonged corticosteroid use, especially in patients with asthma. The report emphasized the necessity for regular ADR monitoring and patient counseling to prevent oral thrush.

Title: Oropharyngeal/Esophageal Candidiasis ("Thrush")

Authors: Centers for Disease Control and Prevention (CDC)

- 8) Findings: Leukotriene receptor antagonists like Montelukast were identified to cause nasal irritation, headache, and gastrointestinal disturbances. The study suggested a need for individualized treatment to minimize these reactions.

Title: Leukotriene Receptor Antagonists and Their Adverse Reactions

Authors: Smith et al.

- 9) Findings: Tremors, a notable ADR with methylxanthines such as Theophylline, were linked to narrow therapeutic windows and high plasma levels. The study recommended regular plasma level monitoring to reduce severe ADR occurrences.

Title: ADR Monitoring in Theophylline Therapy for Asthma Patients

Authors: Gupta R et al.

- 10) Findings: Polypharmacy in asthma treatment increased the risk of drug-drug interactions and compounded ADRs, particularly with combination therapies involving corticosteroids and bronchodilators. Recommendations included prioritizing monotherapy when possible and close ADR monitoring.

Title: Pharmacovigilance in Polypharmacy for Asthma Management

Authors: Patel A et al.

- 11) Findings: Inhaled long-acting beta-agonists (LABAs) like Salmeterol were associated with delayed ADRs, including cardiac palpitations and prolonged QT intervals. The study advised careful ECG monitoring in patients with pre-existing cardiac conditions.

Title: Cardiovascular ADRs in Long-Acting Beta-Agonists Therapy

Authors: Lee K et al.

12) Findings: ADRs such as dizziness, fatigue, and nausea were identified in patients using anticholinergics like Ipratropium. The study suggested that proper dose titration and monitoring could minimize these effects.

Title: Pharmacovigilance Study on Anticholinergic Therapy in Asthma

Authors: Kumar V et al.

VI. ADVERSE DRUG REACTIONS (ADR)

Anti-asthmatic medications can have a range of side effects and toxic effects. These effects can be classified as side effects (common and mild) and toxic effects (more severe or life-threatening).

A. Bronchodilators

Beta-2 Agonists (e.g., Salbutamol, Formoterol, Salmeterol)

1) Side Effects

- Tachycardia (increased heart rate)
- Tremors (shakiness)
- Nervousness or restlessness
- Headache
- Muscle cramps
- Dry mouth (especially with inhalers)

2) Toxic Effects

- Cardiovascular toxicity: High doses or frequent use can lead to arrhythmias, particularly in patients with preexisting heart conditions.
- Hypokalemia: Beta-2 agonists can cause low potassium levels, leading to muscle weakness and arrhythmias.
- Paradoxical bronchospasm: Rare but potentially life-threatening, it involves worsening bronchoconstriction after using the medication.

B. Inhaled Corticosteroids (e.g., Beclometasone, Budesonide, Fluticasone)

1) Side Effects

- Oral thrush (oral candidiasis): Fungal infection in the mouth due to inhaled corticosteroids.
- Hoarseness or voice changes: Due to irritation of the vocal cords.
- Coughing: A common side effect after inhalation.
- Sore throat and nasal irritation.
- Skin bruising: In long-term use.

2) Toxic Effects:

- Systemic effects (with high doses): Can lead to adrenal suppression, osteoporosis, and growth suppression in children.
- Glaucoma: Long-term use may increase intraocular pressure, leading to glaucoma.
- Cataracts: Chronic use can increase the risk of cataract formation.
- Increased risk of infection: Due to immune system suppression.

C. Leukotriene Antagonists (e.g., Montelukast, Zafirlukast)

1) Side Effects:

- Headache and dizziness
- Gastrointestinal upset (nausea, abdominal pain)
- Fatigue and drowsiness
- Skin rash in some cases

2) Toxic Effects

- Neuropsychiatric effects: Rare but serious effects include mood changes, agitation, anxiety, sleep disturbances, and suicidal thoughts.
- Hepatotoxicity: Zafirlukast, in particular, has been linked to liver enzyme elevation and liver damage in some cases.

D. Mast Cell Stabilizers (e.g., Cromolyn, Nedocromil)

1) Side Effects

- Cough or throat irritation after inhalation.
- Dry mouth.
- Nausea or gastrointestinal discomfort.

2) Toxic Effects

- Rare toxic effects, but severe reactions to cromolyn may involve bronchospasm if the drug is inhaled improperly.
- No significant systemic toxicity, as these drugs are usually poorly absorbed into the bloodstream.

E. Methylxanthine

1) Side Effects

- Nausea, vomiting, and diarrhea
- Headache, insomnia, and nervousness
- Increased heart rate (tachycardia)
- Gastroesophageal reflux disease (GERD)

2) Toxic Effects

- Severe arrhythmias (atrial fibrillation, ventricular tachycardia).
- Severe CNS effects: Seizures and confusion at toxic levels.
- Hypokalemia: Similar to beta-2 agonists, excessive theophylline use can lead to low potassium levels, causing muscle weakness or cramps.
- Hepatotoxicity: Rarely, theophylline may cause liver dysfunction, especially in patients with preexisting liver conditions.

F. Immunomodulators (e.g., Omalizumab)

1) Side Effects

- Injection site reactions (pain, redness, swelling).
- Headache.
- Fatigue.
- Upper respiratory tract infections (nasopharyngitis, sinusitis).

2) Toxic Effects

- Anaphylaxis: Although rare, an allergic reaction to omalizumab can cause severe anaphylaxis. Patients are monitored for at least 2 hours after administration.
- Risk of infections: Immunosuppressive effects may increase the risk of certain infections

Drug Class	Side Effects	Toxic Effects
Beta-2 Agonists	Tachycardia, tremors, headache, muscle cramps, dry mouth	Arrhythmias, hypokalemia, paradoxical bronchospasm
Inhaled Corticosteroids (ICS)	Oral thrush, hoarseness, cough, sore throat, bruising	Adrenal suppression, osteoporosis, glaucoma, cataracts
Leukotriene Receptor Antagonists	Headache, dizziness, GI upset, fatigue, skin rash	Neuropsychiatric effects, hepatotoxicity
Mast Cell Stabilizers	Cough, throat irritation, nausea, headache	Bronchospasm (rare)
Theophylline	Nausea, vomiting, insomnia, tachycardia, GERD	Severe arrhythmias, seizures, hepatotoxicity
Immunomodulators (e.g., Omalizumab)	Injection site reactions, headache, fatigue, infections	Anaphylaxis, increased risk of infections

VII. FUTURE SCOPE

- 1) Personalized Pharmacovigilance
- 2) Wearable Health Technology
- 3) Long-Term Safety Studies
- 4) Global Data Sharing and Collaboration
- 5) Post-Marketing Surveillance of Biologics

VIII. CONCLUSION

This pharmacovigilance study on antiasthmatic agents highlight the significant role of monitoring and managing adverse drug reactions (ADRs) to improve patient outcomes. Inhalational corticosteroids, particularly Beclomethasone and Budesonide, are frequently associated with oral thrush, underscoring the importance of preventive measures such as oral hygiene. Beta-2 agonists like Salbutamol and long-acting beta-agonists (LABAs) such as Salmeterol can lead to systemic and cardiac ADRs, necessitating dose optimization and ECG monitoring in at-risk populations. Leukotriene receptor antagonists, methylxanthines, and anticholinergics also exhibit distinct ADR profiles, including headaches, tremors, and nausea, respectively, which emphasize the need for individualized therapy and vigilant monitoring.

REFERENCES

- [1] Kavitha, T., and Shyamala B. "Biologics in Asthma: Safety and Efficacy." *Indian Journal of Pharmacology* 52, no. 6 (2020): 1–12. https://doi.org/10.4103/ijp.ijp_246_19.
- [2] Suissa, Samy. "Inhaled Corticosteroids in Asthma: Benefits and Risks." *Journal of Allergy and Clinical Immunology* 139, no. 5 (2017): 1290–1300. <https://doi.org/10.1016/j.jaci.2017.02.029>.
- [3] Sorkness, Christine A., Eugene R. Bleeker, and William W. Busse. "Asthma Pharmacology: New Drugs and Their Safety Profile." *Journal of Allergy and Clinical Immunology* 136, no. 5 (2015): 1162–70. <https://doi.org/10.1016/j.jaci.2015.07.026>.
- [4] Global Burden of Disease Collaborative Network. *Global Burden of Disease Study 2019 (GBD 2019) Results*. Seattle: Institute for Health Metrics and Evaluation (IHME), 2020. <https://www.globalasthmanetwork.org/publications/gar.php>.
- [5] Turner, Stephen, and Robert Cooper. "Asthma Epidemiology and Genetics." *Respiratory Medicine* 148 (2019): 32–38.
- [6] Beuther, David A., and E. Rand Sutherland. "Overweight, Obesity, and Incident Asthma: A Meta-Analysis of Prospective Cohort Studies." *American Journal of Respiratory and Critical Care Medicine* 174, no. 5 (2011): 647–56.
- [7] Perera, Frederica, Shuang Wang, Julia Vishnevetsky, et al. "Effects of Air Pollution on Asthma and Respiratory Outcomes in Children." *Journal of Allergy and Clinical Immunology* 129, no. 5 (2012): 1160–67.
- [8] Nelson, Kenneth, and Diana Tyler. "The Role of Epidemiology in Understanding Asthma." *American Journal of Epidemiology* 192, no. 7 (2021): 1–11.
- [9] Global Asthma Network. *Global Asthma Report 2022*. Accessed 2022. <https://www.globalasthmanetwork.org/publications/gar.php>.
- [10] Beuther, David A., and E. Rand Sutherland. "Overweight, Obesity, and Incident Asthma: A Meta-Analysis of Prospective Cohort Studies." *American Journal of Respiratory and Critical Care Medicine* 174, no. 5 (2011): 647–56.
- [11] Barnes, Peter J. "Beta-Adrenergic Receptors and the Treatment of Asthma." *Chest* 129, no. 6 (2006): 1294–1301.
- [12] Barnes, Peter J. "Mechanisms in Asthma and COPD: Advances in Therapy." *Chest* 138, no. 2 (2010): 367–74. <https://doi.org/10.1378/chest.10-0621>.
- [13] Global Initiative for Asthma (GINA). *Global Strategy for Asthma Management and Prevention*. 2023. Accessed 2023. <https://ginasthma.org>.
- [14] National Institutes of Health (NIH). *Asthma Treatment and Management*. 2021. Accessed 2021. <https://www.nhlbi.nih.gov/health-topics/asthma>.
- [15] Bellia, Vincenzo, et al. "Side Effects of Asthma Medication: What Is the Evidence?" *The Journal of Allergy and Clinical Immunology* 136, no. 2 (2015): 220–31. <https://doi.org/10.1016/j>.



10.22214/IJRASET



45.98



IMPACT FACTOR:
7.129



IMPACT FACTOR:
7.429



INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Call : 08813907089  (24*7 Support on Whatsapp)